{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-25-000198","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2025-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.237360+00:00","generated_at":"2026-05-17T01:36:23.949624+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Emergent Q3 revenue $231.1M beats guidance; raises FY2025 revenue & EBITDA view","bullets":["Total revenue $231.1M (above Q3 guidance high by $21M); net income $51.2M ($0.91 EPS).","Adjusted EBITDA $87.8M (38% margin); adjusted EPS $1.06; gross margin expanded 300bps to 54%.","Naloxone segment down 21% to $74.9M; MCM down 18% to $142.5M; Other Products up 91% to $57.5M.","FY2025 guidance raised: revenue $775-$835M (from $765-$835M), adjusted EBITDA $195-$210M (from $175-$200M).","Secured $56M ACAM2000, $52M CNJ-016, $30M CYFENDUS, $29M international MCM contracts in Q3."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-25-000198","json":"https://secwatch.observer/filing/0001367644-25-000198.json","markdown":"https://secwatch.observer/filing/0001367644-25-000198.md","text":"https://secwatch.observer/filing/0001367644-25-000198.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764425000198/0001367644-25-000198-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764425000198/ebs-20251029.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:36:23.949624+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}